Bullous Systemic Lupus Erythematosus Successfully Treated With Intravenous Immunoglobulin and Mycophenolate Mofetil.
| Autor: | Chow KW; Internal Medicine, University of Illinois at Chicago, Chicago, USA., Sweis JJG; Internal Medicine, University of Jordan School of Medicine, Amman, USA., Alawneh D; Rheumatology, University of Illinois at Chicago, Chicago, USA., Jetanalin P; Rheumatology, University of Illinois at Chicago, Chicago, USA., Ascoli C; Pulmonary and Critical Care Medicine, University of Illinois at Chicago, Chicago, USA., Kuschel S; Dermatology, University of Illinois at Chicago, Chicago, USA., Hoyer S; Dermatology, University of Illinois at Chicago, Chicago, USA., Braniecki M; Pathology, University of Illinois at Chicago, Chicago, USA., Sweiss N; Rheumatology, University of Illinois at Chicago, Chicago, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Sep 22; Vol. 15 (9), pp. e45800. Date of Electronic Publication: 2023 Sep 22 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.45800 |
| Abstrakt: | Bullous systemic lupus erythematosus (BSLE) is a rare autoimmune blistering disorder of cutaneous lupus erythematosus (CLE) that typically manifests as an acute vesiculobullous eruption in a patient with systemic lupus erythematosus (SLE). Also, it can rarely present as the initial clinical manifestation of SLE. There is no established US Food and Drug Administration (FDA) therapy for BSLE. We report a case of a 71-year-old Hispanic woman with SLE and lupus nephritis classes III and V who presented to the hospital with a worsening rash with painful, ruptured blisters involving the upper arms, chest, and back. Our patient did not respond to topical or systemic steroids but improved rapidly to combination therapy with intravenous immunoglobulin (IVIg) and mycophenolate mofetil (MMF). Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Chow et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|